huperzine a has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S; Lu, L; Wu, J; Ye, W; Zhang, X | 1 |
| Guo, X; Sheng, X; Wang, Q; Wang, Y; Wu, Y; Zhang, J; Zheng, L | 1 |
2 other study(ies) available for huperzine a and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Alkaloids; Animals; Apoptosis; Cholinesterase Inhibitors; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation, Enzymologic; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; PC12 Cells; Rats; Sesquiterpenes; Substantia Nigra | 2013 |
Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Cognition; Disease Models, Animal; Dopaminergic Neurons; Inflammation; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Neuroprotective Agents; Parkinson Disease | 2023 |